China Pharma Holdings (CPHI) Fair Value & Analysis
Healthcare · US · Market cap $31.2M
China Pharma Holdings
CPHI · US
Fair value as of: Jul 15, 2026
From 6 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $2.53 to $0.3800 (−85.0%) since Jun 24, 2026. Share price −13.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.5200 – $2.00 · fair‑value band $0.2800 – $0.5600 · the $0.6148 price screens above the $0.3800 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
China Pharma Holdings (CPHI) currently trades at $0.6148, while our model-based Fair Value estimate is $0.3800 — implying the stock looks roughly 38.2% overvalued today. We read business quality at 29/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, China Pharma Holdings generated revenue of $4.0M at a net margin of -88.8%. Revenue declined 13.4% year over year. It earns a return on equity of -16.1%. Net debt stands at $3.5M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $0.2800 (bear case) to $0.5600 (bull case); at $0.6148, the current price sits above that range. The share trades about 70% below its 52-week high and 23% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at -38%, CPHI screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
China Pharma Holdings reported revenue of $4.1M in FY2025 versus $9.6M in FY2021, a compound −19.0%/yr. Reported net income was −$3.2M in FY2025.
Is CPHI fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$32.56 | HK$15.58 | -52% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is China Pharma Holdings (CPHI) undervalued?
What is the fair value of CPHI?
What is the quality score of CPHI?
What is the revenue of China Pharma Holdings (CPHI)?
What is the net profit margin of CPHI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full China Pharma Holdings analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.